Thumbnail
Access Restriction
Subscribed

Author Salgado, Claudio G. ♦ da Silva, Moises B. ♦ Yamano, Suellen S. P. ♦ Salgado, Ubirajara I. ♦ Diniz, José A. P. ♦ da Silva, Jorge P.
Source World Health Organization (WHO)-Global Index Medicus
Content type Text
Publisher Wiley
File Format HTM / HTML
Language English
Difficulty Level Medium
Subject Domain (in DDC) Natural sciences & mathematics ♦ Chemistry & allied sciences ♦ Life sciences; biology ♦ Biochemistry ♦ Natural history of organisms ♦ Technology ♦ Medicine & health ♦ Pharmacology and therapeutics ♦ Diseases
Subject Domain (in MeSH) Eukaryota ♦ Organisms ♦ Bacterial Infections and Mycoses ♦ Diseases ♦ Heterocyclic Compounds ♦ Chemical Actions and Uses ♦ Chemicals and Drugs ♦ Therapeutics ♦ Analytical, Diagnostic and Therapeutic Techniques and Equipment ♦ Persons ♦ Persons
Subject Keyword Discipline Pathology ♦ Discipline Dermatology ♦ Antifungal Agents ♦ Pharmacology ♦ Ascomycota ♦ Chromoblastomycosis ♦ Itraconazole ♦ Mitosporic Fungi ♦ Administration, Cutaneous ♦ Drug Therapy ♦ Microbiology ♦ Pathology ♦ Humans ♦ Male ♦ Middle Aged ♦ Case Reports ♦ Journal Article ♦ Research Support, Non-u.s. Gov't
Abstract Chromoblastomycosis (CBM) is a difficult-to-treat dermal mycosis characterized by the presence of round, pigmented, sclerotic bodies formed by black fungi found in polymorphic lesions. According to the morphology of a lesion, different clinical types of the disease have been described. We present three patients who each developed a single, 10-cm diameter, 8 to 15-year-old, well-circumscribed, slow-growing, annular, papulosquamous or papulosquamous-verrucous lesion, with no regression despite the use of topical antifungals. Skin scrapings and biopsies confirmed CBM and microculture defined the agent as Fonsecaea pedrosoi. The patients were treated with 200 mg/day of itraconazole for 6-9 months and were discharged after complete regression of the lesions. All were examined after the first and second year of the end of treatment and there were no signs of recurrence. A new clinical type of CBM is described, and itraconazole appears to be effective and safe in curing these patients after no more than 9 months of therapy.
Description Country affiliation: Brazil
Author Affiliation: Salgado CG ( Dermato-Immunology Laboratory UEPA/UFPA/Marcello Candia, Marituba, Pará, Brazil. csalgado@ufpa.br)
ISSN 03036987
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Reading ♦ Research ♦ Self Learning
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Case study ♦ Article
Publisher Date 2009-02-01
Publisher Place United States
e-ISSN 16000560
Journal Journal of Cutaneous Pathology
Volume Number 36
Issue Number 2


Open content in new tab

   Open content in new tab
Source: WHO-Global Index Medicus